Latest News

Latest News2018-07-31T19:14:53+01:00

Mirai Medical Announces First Patient Enrolled in VECTOR Trial using ePORE® therapy for the Treatment of Inoperable Oesophageal and Gastric Cancer

April 15th, 2021|

Mirai Medical Ltd, a manufacturer of a precision cancer therapy platform , today announced the first procedures in the clinical trial to evaluate ePORE® therapy and EndoVE®, a novel breakthrough technology that can treat gastrointestinal cancers endoscopically in an outpatient setting with minimum hospitalisation for the patient. The first procedure in the VECTOR trial (NCT04649372) was performed this week at Nottingham NHS Trust, United Kingdom in a team led by [...]

Aruna Bio Closes $10.8 Million Common Stock Financing

April 14th, 2021|

ATHENS, Ga. and RESEARCH TRIANGLE PARK, N.C., April 14, 2021 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in the development of neural exosomes for the treatment of neurodegenerative diseases, today announced the closing of a common stock financing totalling $10.8 million. Proceeds from the raise will support the company’s business plan through mid-2022. “This capital will allow us to continue our efforts to deliver important therapeutics to the central nervous [...]

Longboat Clinical acquired in multimillion euro deal

November 26th, 2020|

Serial entrepreneur Gerard Ryan, who sold his previous company to Dublin-listed Icon for €50 million, has agreed another multimillion euro sale, with US company Advarra buying his latest business Longboat Clinical. The pharmatech start-up has been acquired by Advarra for an undisclosed sum, although informed sources said it represented one of the biggest M&A deals in Ireland this year. Longboat, which has facilities in Dublin and Limerick, has developed a [...]

Digital pathology start-up Deciphex raises $6.2m for R&D

July 3rd, 2020|

Deciphex, an Irish tech company that develops software to accelerate the delivery of pathology services, has raised $6.2 million (€5.4 million) to further accelerate research and development and market entry. This brings total funding to date to nearly €8 million for a company that was founded in 2017 by Dr Donal O’Shea.   Read Full Article from Irish Times

43% of Female Angel Investors Eye Up Exits Next Year

November 6th, 2019|Tags: , |

43% of Female Angel Investors Eye Up Exits Next Year HBAN today reveals that 43% of female angel investors are eyeing up exits from their investee companies in the next 12 months. Read Full Article from HBAN Author: Date: November 6, 2019 Provided By: https://www.hban.org/_shared/news/RSSNewsPage.aspx?Id=9

Diaceutics PLC Dublin Investor Event

October 11th, 2019|Tags: , |

Diaceutics PLC Dublin Investor Event Diaceutics PLC will hold an investor presentation in Dublin on Tuesday, 29 October 2019. Diaceutics PLC is a leading diagnostics data analytics and implementation services provider for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling Pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to [...]

HBAN’s MedTech Syndicate led initial €1.2M investment in Bluedrop Medical

September 19th, 2019|Tags: , |

HBAN's MedTech Syndicate led initial €1.2M investment in Bluedrop Medical HBAN announces that Bluedrop Medical, a Galway based Medical device start up, has secured €3.7M in funding to help manage one of the most devastating complications of diabetes – the diabetic foot. An initial seed investment of €1.2M was led by HBAN’s MedTech Syndicate - which itself invested €340K in the seed round. Enterprise Ireland and the Western Development Commission [...]

CroíValve Secures €4M in Additional Funding to Initiate Clinical Trials

September 12th, 2019|Tags: , |

CroíValve Secures €4M in Additional Funding to Initiate Clinical Trials HBAN investors have contributed towards €4 million in additional financing that has been secured by CroíValve, a high potential start-up (HPSU) supported by Enterprise Ireland developing a treatment for tricuspid regurgitation (TR). This is an issue affecting over half-a-million people every year in the US and EU alone, for which there is currently no suitable solution. The financing includes €2.5 [...]

If you are interested in becoming an Investor or seeking investment, then please contact us.

Go to Top